Cargando…
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
BACKGROUND: Tuberous sclerosis (TS) is a rare autosomal dominant systemic disease with an estimated prevalence of 1/6000. Renal angiomyolipoma (AML) is a benign tumour with high morbidity frequently present in TS. The aim of the study was to test the effect of rapamycin in reducing the volume of AML...
Autores principales: | Cabrera-López, Cristina, Martí, Teresa, Catalá, Violeta, Torres, Ferran, Mateu, Silvia, Ballarín, Jose, Torra, Roser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519505/ https://www.ncbi.nlm.nih.gov/pubmed/23140536 http://dx.doi.org/10.1186/1750-1172-7-87 |
Ejemplares similares
-
Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex
por: Buj Pradilla, María José, et al.
Publicado: (2017) -
Large renal angiomyolipomas in tuberous sclerosis
por: Esson, G, et al.
Publicado: (2023) -
Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated
por: Cabrera-López, Cristina, et al.
Publicado: (2015) -
Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial
por: Robles, Nicolás Roberto, et al.
Publicado: (2016) -
Tuberous sclerosis with bilateral giant renal angiomyolipomas
por: Kumar, Suresh, et al.
Publicado: (2016)